Immunotherapy for Head and Neck Cancer / Cancer Immunotherapy Bd.1 (PDF)

Anthony Chan, MD, FRCP (Lond, Edin, Glas), graduated from the School of Medicine at University College London and received his post-graduate training in Medical Oncology at the Royal Marsden Hospital, UK. He joined the Chinese University of Hong Kong in 1993, where he is currently Li Shu Fan Professor of Clinical Oncology, Director of the Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Chief Director of Phase 1 Clinical Trial Centre, Associate Director of the State Key Laboratory for Translational Oncology, Dean of the Graduate School and Master of Wu Yee Sun College.
Professor Chan conducted pivotal studies defining new treatment standards for multimodality approaches to nasopharynx cancer, developed the clinical applications of the biomarker EBV DNA and pioneered the development of immunotherapeutic and targeted therapeutics for this disease. He has published over 400 peer-reviewed papers, 53 book chapters and reviews, and given over 170 international lectures. He has served on the Editorial Board of the Journal of Clinical Oncology and has been an Associate Editor of Annals of Oncology since 2014.





Professor Chan has served on various ESMO committees covering head and neck and immuno-oncology. He was co-chair of the scientific steering committee of the first ESMO Asia Congress in 2015. He is chairman of the scientific sub-committee of Head and Neck for ESMO 2020 and educational co-chair of ESMO Asia 2020.

Brigette Ma is currently Professor and Honorary Consultant at the Department of Clinical Oncology, Chinese University of Hong Kong (CUHK), Medical Director of the Phase I Clinical Trial Centre (Oncology), Co-Director of the Cancer Drug Testing Unit and Chair (Phase 1) of the NTEC-CUHK ethics committee. She received her Bachelor's degree with honors from Monash University, Australia, and was appointed a fellow of the Royal Australasian College of Physicians, a fellow of the Hong Kong College of Physicians, and a